SRT 1720 Hydrochloride - CAS# 1001645-58-4 Catalog No.:M10734-2 Trametinib specifically binds to and

Trametinib specifically binds to and inhibits MEK 1 and 2

3)17-21-14-10-5-4-9(19)8-12(10)13-11(15(14)22-17)6-7-20-16(13)23/h4-8H

Smiles: CCCCCCCCCCCCC1C=CC(=CC=1)S(=O)(=O)NC1=NN=CS1

5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3

Chemical Name: 3-[6-(morpholin-4-yl)-8-oxa-3

SRT 1720 Hydrochloride - CAS# 1001645-58-4 Catalog No.:M10734-2 Trametinib specifically binds to andSRT 1720, also known as CAY10559 and is a drug developed by Sirtris Pharmaceuticals intended as a small molecule activator of the sirtuin subtype SIRT1. It has similar activity in the body to the known SIRT1 activator resveratrol, but is 1000x more potent. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function. A study of SRT1720